Health Care Equipment

Livanova

LivaNova Executives to Speak at Goldman Sachs Global Healthcare Conference on June 8

Livanova released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 362.3 M (forecast USD 346.11 M), actual EPS USD 0.4 (forecast USD 0.6)

Livanova to release FY2026 Q1 earnings report on May 6 Pre-Market EST, forecast revenue USD 346.11 M, EPS USD 0.6

Peregrine Capital Management LLC Invests in LivaNova PLC in Q4

Livanova released FY2025 annual earnings on February 25 Pre-Market (EST), actual revenue USD 1.388 B (forecast USD 1.379 B), actual EPS USD -4.45 (forecast USD -3.3583)

Livanova released FY2025 Q4 earnings on February 25 Pre-Market (EST), actual revenue USD 360.9 M (forecast USD 354.31 M), actual EPS USD 0.56 (forecast USD 0.426)

Livanova to release FY2025 Q4 earnings on February 25, Pre-Market EST, with forecasted revenue of USD 354.31 M and EPS of USD 0.426

LivaNova PLC to present real-world evidence of VNS therapy at AES Annual Meeting

Livanova released FY2025 9 Months Earnings on November 5 Pre-Market EST, actual revenue USD 1.027 B, actual EPS USD -5.0269

Livanova released FY2025 Q3 earnings on November 5 Pre-Market (EST), actual revenue USD 357.75M (forecast USD 342.32M), actual EPS USD 0.49 (forecast USD 0.5375)

Livanova to Release FY2025 Q3 Earnings on November 5, Pre-Market EST; Forecast Revenue USD 342.72M, EPS USD 0.5375

Livanova released FY2025 Q2 earnings on August 6 Pre-Market EST, actual revenue USD 352.52 M (forecast USD 332.21 M), actual EPS USD 0.4976 (forecast USD 0.51)

Livanova released FY2025 Semi-Annual earnings on August 6 Pre-Market (EST), actual revenue USD 669.38 M, actual EPS USD -5.51

LivaNova PLC Reports Financials and Treatment Reassessments

Livanova to Release FY2025 Q2 Earnings on August 6, 2025 Pre-Market EST, Forecast Revenue USD 332.21 M, EPS USD 0.51

LivaNova Receives Analyst Buy Recommendations

LivaNova PLC Receives Analyst Buy Rating

LivaNova PLC's Annual Shareholders Meeting Approves Multiple Proposals

Twinbeech Capital 大幅减持 LivaNova 股票

LivaNova faces environmental disputes over merger, remanded by Italian Supreme Court

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

LIVN

LivaNova PLC appointed Jette Nygaard-Andersen to its Board and Anne Liddy as Chief Legal Officer, while Dr. Sharon O’Kane stepped down. These governance changes aim to strengthen oversight in medtech, legal, and compliance areas, potentially aiding regulatory management. However, the core investment narrative remains focused on neuromodulation growth and managing pricing pressures, with analysts projecting $1.8 billion revenue by 2029.

Simplywall

Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook?

Rhenman & Partners Asset Management AB increased its stake in LivaNova PLC by 258.5% in Q4, acquiring 137,000 shares to hold 190,000 valued at $11.69 million. Other institutions like Goldman Sachs and UBS also raised positions. Meanwhile, Director Francesco Bianchi sold 1,800 shares. LivaNova recently reported strong earnings, beating estimates with $0.98 EPS and $362.26M revenue. Analysts have adjusted price targets, with Needham raising theirs to $81.

Market Beat

UBS Group AG

Goldman Sachs

Stifel Financial

Barclays

GS Hldg R

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Rhenman & Partners Asset Management AB Purchases 137,000 Shares of LivaNova PLC $LIVN

LivaNova shareholders approved key proposals at the 2026 AGM, including director elections, executive compensation reports, and auditor appointments. The board received authorization for share allotments, pre-emption rights disapplication, and buybacks up to 10% of shares. Analysts maintain a 'Hold' rating with a $76 target, while TipRanks' AI suggests 'Outperform' based on improved fundamentals and raised guidance.

Tip Ranks

LivaNova Shareholders Back 2026 AGM Proposals and Governance

LivaNova PLC announced the election of Jette Nygaard-Andersen to its Board of Directors following the June 10 Annual General Meeting. Nygaard-Andersen brings extensive medtech governance and CEO leadership experience. Concurrently, Dr. Sharon O’Kane stepped down after a decade of service. The announcement also detailed changes in board committee chairmanships, including Brooke Story succeeding O’Kane as Chair of the Nominating and Corporate Governance Committee.

StockTitan

Entain PLC

Entain Plc

Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LIVN Stock News

LivaNova PLC (Nasdaq: LIVN) announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee global legal and compliance functions and join the Executive Leadership Team. She brings over two decades of experience from Hologic, Inc., where she served as General Counsel. CEO Vladimir Makatsaria praised her expertise in healthcare regulatory matters, stating her leadership will support the company's strategic priorities and sustainable growth.

Hologic

Pfizer

LivaNova Appoints Anne Liddy as Chief Legal Officer | LIVN Stock News

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LIVN Stock News

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LIVN Stock News

LivaNova (LIVN) reported Q1 2026 revenue of $362.3 million and basic EPS of $0.41, marking a return to profitability after a loss of $6.01 per share in Q1 2025. The company achieved a trailing twelve-month revenue of $1.4 billion and a net income turnaround from a loss of $242.5 million to a profit of $107.1 million. Despite bullish narratives around new therapies and revenue growth, concerns remain about the high P/E ratio of 33.8x compared to industry averages, raising questions about valuation risks and the sustainability of recent earnings improvements.

LivaNova (LIVN) Profit Return And 33.8x P E Test Bullish Narratives

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.98 EPS, exceeding estimates by $0.13, with revenue of $362.30 million, up 14.3% year-over-year. The company raised its FY 2026 guidance to $4.20–$4.30 EPS and 7%–8% revenue growth, driven by strong Q1 performance. Key growth areas include cardiopulmonary and epilepsy segments, with positive Medicare reimbursement changes. However, cash flow pressures were noted, with adjusted free cash flow at $4 million. Following the earnings report, LivaNova's stock rose 15.1% to $66.26, reflecting positive investor sentiment.

LivaNova (NASDAQ:LIVN) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

LivaNova PLC reported a revenue of $362.26M for Q1 2026, marking a 14.3% increase from the previous year, with a diluted EPS of $0.4 compared to a loss of $6.01 in Q1 2025. The company achieved a net income of $22.29M, recovering from a loss of $327.32M a year ago. Growth was driven by strong demand in the U.S. and Europe, particularly in the cardiopulmonary and neuromodulation segments. R&D investments increased to support new developments, while operations remained stable despite global challenges.

TradingView

LivaNova PLC 1Q 2026: Revenue $362.26M, EPS $0.4— 10-Q Summary

LivaNova shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 adjusted EPS and FY2026 sales guidance above estimates.

benzinga_article

Livanova(LIVN.US)

Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook?

Rhenman & Partners Asset Management AB Purchases 137,000 Shares of LivaNova PLC $LIVN

LivaNova Shareholders Back 2026 AGM Proposals and Governance

Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LIVN Stock News

LivaNova Appoints Anne Liddy as Chief Legal Officer | LIVN Stock News

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LIVN Stock News

LivaNova (LIVN) Profit Return And 33.8x P E Test Bullish Narratives

LivaNova (NASDAQ:LIVN) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

LivaNova PLC 1Q 2026: Revenue $362.26M, EPS $0.4— 10-Q Summary

LivaNova shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 adjusted EPS and FY2026 sales guidance above estimates.